Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 106 of 1,261
  1. US 12036269

    Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria

    The Board of Regents of the University of Texas System Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  2. US 12037390

    Leptin antibodies and method of reducing leptin

    The Board of Regents of the University of Texas System Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  3. US 12037374

    Peptides, hydrogel compositions and methods of use thereof

    Regents of the University of Minnesota Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  4. US 12036288

    Methods of using humanized FCΞ³R mice to assay Fc regions

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  5. US 12036283

    Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

    Nektar Therapeutics Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  6. US 12037401

    Anti-TrkB monoclonal antibodies and methods of use

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  7. US 12037363

    Peptides for Covid-19 prevention and treatment

    SOTIRA COVID, LLC Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  8. US 12036278

    Smallpox vaccine for cancer treatment

    Calidi Biotherapeutics (Nevada), Inc. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  9. US 12036205

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Amazentis SA Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  10. US 12036266

    Activatable cytokine polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  11. US 12036314

    Compositions and methods for in situ-forming tissue constructs

    United States Government as represented by the Department of Veterans Affairs Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  12. US 12036231

    Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling

    The Board of Regents of the University of Texas System Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  13. US 12036280

    High concentration protein formulation

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  14. US 12037411

    Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  15. US 12036194

    Methods of administering solriamfetol to lactating women

    AXSOME MALTA LTD. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  16. US 12037388

    Anti-IL-33 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  17. US 12036319

    Polyvalent sting activating compositions and uses thereof

    The Board of Regents of the University of Texas System Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  18. US 12038433

    Methods and apparatus for high-throughput screening for testing permeability and retention of compounds across biological barriers

    The Board of Regents of the University of Texas System Β· Granted Jul 16, 2024 Β· Expires Jul 11, 2044

    granted
  19. WO 2024146923

    INHIBITEURS DE POLYMÉRISATION DE TUBULINE

    AB SCIENCE [FR] Β· Granted Jul 11, 2024 Β· Expires Jul 6, 2044

    granted
  20. US 12031157

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  21. US 12031130

    Composition for modifying target gene

    Takeda Pharmaceutical Company Limited Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  22. US 12030970

    Curable composition and stereolithographic resin composition comprising same

    KURARAY CO., LTD. Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  23. US 12031136

    Treatment for skeletal diseases caused by intracellular protein trafficking defects

    The Board of Regents of the University of Oklahoma Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  24. US 12030940

    Immunotherapeutic tumor treatment method

    Nektar Therapeutics Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.